Journal article
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
BCV Campbell, PJ Mitchell, L Churilov, N Yassi, TJ Kleinig, RJ Dowling, B Yan, SJ Bush, HM Dewey, V Thijs, R Scroop, M Simpson, M Brooks, H Asadi, TY Wu, DG Shah, T Wijeratne, T Ang, F Miteff, CR Levi Show all
NEW ENGLAND JOURNAL OF MEDICINE | MASSACHUSETTS MEDICAL SOC | Published : 2018
Abstract
BACKGROUND: Intravenous infusion of alteplase is used for thrombolysis before endovascular thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer activity than alteplase, is given as a bolus and may increase the incidence of vascular reperfusion. METHODS: We randomly assigned patients with ischemic stroke who had occlusion of the internal carotid, basilar, or middle cerebral artery and who were eligible to undergo thrombectomy to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or alteplase (at a dose of 0.9 mg per kilogram; maximum dose, 90 mg) within 4.5 hours after symptom onset. The primary outcome was repe..
View full abstractRelated Projects (4)
Grants
Funding Acknowledgements
Funded by the National Health and Medical Research Council of Australia and others; EXTEND-IA TNK ClinicalTrials.gov number, NCT02388061.